September 19, 2021 10:02 AM EDTUpdated September 19, 08:02 PM

Mirati's KRAS drug looks like the early favorite in colon cancer with new data, putting the pressure square on Amgen

Kyle Blankenship

With Amgen already providing proof-of-concept for KRAS inhibitors with its sotorasib, Mirati Therapeutics is piecing together a follow-up effort in lung cancer with data it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mirati's KRAS drug looks like the early favorite in colon cancer with new data, putting the pressure square on Amgen

Kyle Blankenship

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Mi­rati's KRAS drug looks like the ear­ly fa­vorite in colon can­cer with new da­ta, putting the pres­sure square on Am­gen

Kyle Blankenship

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Mirati's KRAS drug looks like the early favorite in colon cancer with new data, putting the pressure square on Amgen

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data